{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T10:07:46Z","timestamp":1793614066796,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Sohag University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Conventional therapies for systemic lupus erythematosus (SLE) often fail to achieve lasting remission. CAR T cell therapy, which depletes autoreactive B cells, offers a novel approach for refractory cases. We aim to consolidate the current evidence on CAR T cell therapy in the treatment of SLE. PubMed, Scopus, Web of Science, the Cochrane Library, and Clinical trials.gov were searched up to November 18, 2024, for SLE patients receiving CAR T cell therapy. Data on efficacy, safety, and treatment responses were analyzed. Ten studies involving 47 SLE patients were identified. Among those patients, 81% achieved lupus low disease activity state (LLDAS) with improvements in disease activity and serologic markers. B cell depletion was consistent, with immune recovery over time. Cytokine release syndrome (CRS) occurred in 87% but was mostly mild (grades 1\u20132). Immune effector cell-associated neurotoxicity syndrome (ICANS) occurred only in one patient and was mild (grade 1). CAR T cell therapy shows promise in refractory SLE, achieving durable remission with manageable toxicity. Further trials are needed to confirm long-term outcomes.<\/jats:p>","DOI":"10.1007\/s00210-025-04425-z","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T15:33:34Z","timestamp":1755185614000},"page":"1565-1588","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["CAR T cell therapy efficacy and safety in SLE: a systematic review and pooled analysis of 47 patients across 10 studies"],"prefix":"10.1007","volume":"399","author":[{"given":"Omima Ahmed","family":"Sayed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3949-8067","authenticated-orcid":false,"given":"Mohamed","family":"Ellebedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Ahmed","family":"Abu-Alsaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amro Issam Bakri","family":"Meligy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamer A.","family":"Gheita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,14]]},"reference":[{"issue":"10","key":"4425_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103648","volume":"23","author":"L Arnaud","year":"2024","unstructured":"Arnaud L, Chasset F, Martin T (2024) Immunopathogenesis of systemic lupus erythematosus: an update. Autoimmun Rev 23(10):103648","journal-title":"Autoimmun Rev"},{"issue":"3","key":"4425_CR2","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s40744-020-00212-9","volume":"7","author":"F Basta","year":"2020","unstructured":"Basta F, Fasola F, Triantafyllias K, Schwarting A (2020) Systemic lupus erythematosus (SLE) therapy: the old and the new. Rheumatol Ther 7(3):433\u2013446","journal-title":"Rheumatol Ther"},{"issue":"3","key":"4425_CR3","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.rdc.2021.04.006","volume":"47","author":"SP Canny","year":"2021","unstructured":"Canny SP, Jackson SW (2021) B cells in systemic lupus erythematosus: from disease mechanisms to targeted therapies. Rheum Dis Clin North Am 47(3):395\u2013413","journal-title":"Rheum Dis Clin North Am"},{"key":"4425_CR4","doi-asserted-by":"publisher","unstructured":"Chen YJ, Abila B, Mostafa Kamel Y. (2023) CAR-T: What is next? cancers (Basel) 15(3):663.\u00a0https:\/\/doi.org\/10.3390\/cancers15030663","DOI":"10.3390\/cancers15030663"},{"key":"4425_CR5","doi-asserted-by":"crossref","unstructured":"Cort\u00e9s Hern\u00e1ndez J, Barba P, Linares Alberich M, Fischer O, Kovacs B, Calzascia T, Pearson D, Jord\u00e1n Garrote A, Kirsil\u00e4 T, SiegelR, Shisha T, Cavalli G, Gergely P (2023) An open-label, multicenter, phase 1\/2 study to assess safety, efficacy and cellular kinetics of YTB323, a rapid manufacturing CAR-T Cell Therapy Targeting CD19 on B Cells, for severe refractory systemic lupus erythematosus: Preliminary results [abstract]. Arthritis Rheumatol 75(suppl 9). https:\/\/acrabstracts.org\/abstract\/an-openlabel-multicenter-phase-1-2-study-to-assess-safety-efficacy-and-cellular-kinetics-of-ytb323-a-rapid-manufacturing-car-t-cell-therapytargeting-cd19-on-b-cells-for-severe-refractory-system\/. Accessed 2 Jul 2025","DOI":"10.1136\/annrheumdis-2024-eular.1768"},{"key":"4425_CR6","doi-asserted-by":"crossref","unstructured":"Cort\u00e9s-Hern\u00e1ndez et al (2024) An open-label, multicenter, phase 1\/2 study to assess safety, efficacy and cellular kinetics of YTB323, a rapid manufacturing CAR-Tcell therapy targeting CD19 on B cells, for severe refractory systemic lupus erythematosus: preliminary results - ACR Meeting Abstracts [Internet]. [cited 2025 Feb 6]. Available from: https:\/\/acrabstracts.org\/abstract\/an-open-label-multicenter-phase-1-2-studyto-assess-safety-efficacy-and-cellular-kinetics-of-ytb323-a-rapid-manufacturing-car-t-cell-therapy-targeting-cd19-on-b-cells-forsevere-refractory-system\/","DOI":"10.1136\/annrheumdis-2024-eular.1768"},{"issue":"Supplement 1","key":"4425_CR7","doi-asserted-by":"publisher","first-page":"4835","DOI":"10.1182\/blood-2023-186669","volume":"142","author":"J Feng","year":"2023","unstructured":"Feng J, Hu Y, Chang AH, Huang H (2023) CD19\/BCMA CAR-T cell therapy for refractory systemic lupus erythematosus - safety and preliminary efficacy data from a phase I clinical study. Blood 142(Supplement 1):4835\u20134835","journal-title":"Blood"},{"issue":"2","key":"4425_CR8","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1080\/08916934.2019.1700232","volume":"53","author":"Y Feng","year":"2020","unstructured":"Feng Y, Yang M, Wu H, Lu Q (2020) The pathological role of B cells in systemic lupus erythematosus: from basic research to clinical. Autoimmunity 53(2):56\u201364","journal-title":"Autoimmunity"},{"issue":"5","key":"4425_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2024.105702","volume":"91","author":"A Guffroy","year":"2024","unstructured":"Guffroy A, Jacquel L, Guffroy B, Martin T (2024) CAR-T cells for treating systemic lupus erythematosus: a promising emerging therapy. Joint Bone Spine 91(5):105702","journal-title":"Joint Bone Spine"},{"issue":"10468","key":"4425_CR10","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1016\/S0140-6736(24)02265-7","volume":"404","author":"M Hagen","year":"2024","unstructured":"Hagen M, M\u00fcller F, Wirsching A, Kharboutli S, Sp\u00f6rl S, Aigner M et al (2024) Treatment of CNS systemic lupus erythematosus with CD19 CAR T cells. Lancet 404(10468):2158\u20132160","journal-title":"Lancet"},{"issue":"1","key":"4425_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103692","volume":"24","author":"X He","year":"2025","unstructured":"He X, Hu B, Zhang Y, Liu F, Li Q, Zheng C et al (2025) Treatment of two pediatric patients with refractory systemic lupus erythematosus using CD19-targeted CAR T-cells. Autoimmun Rev 24(1):103692","journal-title":"Autoimmun Rev"},{"issue":"8","key":"4425_CR12","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1038\/s41423-020-0472-1","volume":"18","author":"X Jin","year":"2021","unstructured":"Jin X, Xu Q, Pu C, Zhu K, Lu C, Jiang Y et al (2021) Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus. Cell Mol Immunol 18(8):1896\u20131903","journal-title":"Cell Mol Immunol"},{"issue":"8","key":"4425_CR13","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1007\/s00296-023-05306-5","volume":"43","author":"P-B Katarzyna","year":"2023","unstructured":"Katarzyna P-B, Wiktor S, Ewa D, Piotr L (2023) Current treatment of systemic lupus erythematosus: a clinician\u2019s perspective. Rheumatol Int 43(8):1395\u20131407","journal-title":"Rheumatol Int"},{"issue":"1","key":"4425_CR14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jtct.2022.10.004","volume":"29","author":"S Kretschmann","year":"2023","unstructured":"Kretschmann S, V\u00f6lkl S, Reimann H, Kr\u00f6nke G, Schett G, Achenbach S et al (2023) Successful generation of CD19 chimeric antigen receptor T cells from patients with advanced systemic lupus erythematosus. Transplant Cell Ther 29(1):27\u201333","journal-title":"Transplant Cell Ther"},{"issue":"10437","key":"4425_CR15","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/S0140-6736(24)00424-0","volume":"403","author":"T Krickau","year":"2024","unstructured":"Krickau T, Naumann-Bartsch N, Aigner M, Kharboutli S, Kretschmann S, Spoerl S et al (2024) CAR T-cell therapy rescues adolescent with rapidly progressive lupus nephritis from haemodialysis. Lancet 403(10437):1627\u20131630","journal-title":"Lancet"},{"issue":"4","key":"4425_CR16","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1056\/NEJMc2403743","volume":"391","author":"M Li","year":"2024","unstructured":"Li M, Zhang Y, Jiang N, Ning C, Wang Q, Xu D et al (2024) Anti-CD19 CAR T cells in refractory immune thrombocytopenia of SLE. N Engl J Med 391(4):376\u2013378","journal-title":"N Engl J Med"},{"key":"4425_CR17","doi-asserted-by":"crossref","unstructured":"Los-Arcos I, Iacoboni G, Aguilar-Guisado M, Alsina-Manrique L, D\u00edaz de Heredia C, Fortuny-Guasch C et al (2021) Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper. Infection 49(2):215\u201331","DOI":"10.1007\/s15010-020-01521-5"},{"issue":"5","key":"4425_CR18","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1093\/rheumatology\/kead616","volume":"63","author":"X Lyu","year":"2024","unstructured":"Lyu X, Gupta L, Tholouli E, Chinoy H (2024) Chimeric antigen receptor T cell therapy: a new emerging landscape in autoimmune rheumatic diseases. Rheumatology (Oxford) 63(5):1206\u20131216","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"4425_CR19","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","volume":"28","author":"A Mackensen","year":"2022","unstructured":"Mackensen A, M\u00fcller F, Mougiakakos D, B\u00f6ltz S, Wilhelm A, Aigner M et al (2022) Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med 28(10):2124\u20132132","journal-title":"Nat Med"},{"key":"4425_CR20","doi-asserted-by":"crossref","unstructured":"Marasco E, Bracaglia C, Merli P, Alvarez PM, Nicolai R, Algeri M, et al (2024) P101\u2005Anti-CD19 CAR-T cell therapy for refractory childhood-onset systemic lupus erythematosus. Poster Presentations. Lupus Foundation of America, pp A113.1\u2013A113","DOI":"10.1136\/lupus-2024-el.155"},{"issue":"2","key":"4425_CR21","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","volume":"22","author":"EC Morris","year":"2022","unstructured":"Morris EC, Neelapu SS, Giavridis T, Sadelain M (2022) Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol 22(2):85\u201396","journal-title":"Nat Rev Immunol"},{"key":"4425_CR22","doi-asserted-by":"crossref","unstructured":"Mougiakakos D, Meyer E, Schett G (2024) CAR T-cells in autoimmunity: game changer or stepping stone? Blood","DOI":"10.1182\/blood.2024025413"},{"issue":"8","key":"4425_CR23","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F M\u00fcller","year":"2024","unstructured":"M\u00fcller F, Taubmann J, Bucci L, Wilhelm A, Bergmann C, V\u00f6lkl S et al (2024) CD19 CAR T-cell therapy in autoimmune disease - a case series with follow-up. N Engl J Med 390(8):687\u2013700","journal-title":"N Engl J Med"},{"issue":"10","key":"4425_CR24","first-page":"2127","volume":"18","author":"Z Munn","year":"2020","unstructured":"Munn Z, Barker TH, Moola S, Tufanaru C, Stern C, McArthur A et al (2020) Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Evid Synth 18(10):2127\u20132133","journal-title":"JBI Evid Synth"},{"key":"4425_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2024.152479","volume":"67","author":"R Ohno","year":"2024","unstructured":"Ohno R, Nakamura A (2024) Advancing autoimmune rheumatic disease treatment: CAR-T cell therapies - evidence, safety, and future directions. Semin Arthritis Rheum 67:152479","journal-title":"Semin Arthritis Rheum"},{"key":"4425_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"29","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 29:n71","journal-title":"BMJ"},{"key":"4425_CR27","doi-asserted-by":"crossref","unstructured":"Podoll A, Furie R, Kim F, Chou J, Sengupta R, Bayer R, et al (2024) P95\u2005first two US patients with lupus nephritis (LN) treated with anti-CD19 chimeric antigen receptor (CAR) T-cell therapy: preliminary results from the KYSA-1 phase 1, multicenter study of KYV-101. Poster Presentations. Lupus Foundation of America. p A109\u201310","DOI":"10.1136\/lupus-2024-el.149"},{"issue":"1","key":"4425_CR28","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41409-024-02429-6","volume":"60","author":"A Rampotas","year":"2025","unstructured":"Rampotas A, Richter J, Isenberg D, Roddie C (2025) CAR-T cell therapy embarks on autoimmune disease. Bone Marrow Transplant 60(1):6\u20139","journal-title":"Bone Marrow Transplant"},{"issue":"Suppl5","key":"4425_CR29","doi-asserted-by":"publisher","first-page":"v69","DOI":"10.1093\/rheumatology\/keaa403","volume":"59","author":"G Ruiz-Irastorza","year":"2020","unstructured":"Ruiz-Irastorza G, Bertsias G (2020) Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs. Rheumatology (Oxford) 59(Suppl5):v69-81","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"4425_CR30","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1472-6947-7-16","volume":"15","author":"C Schardt","year":"2007","unstructured":"Schardt C, Adams MB, Owens T, Keitz S, Fontelo P (2007) Utilization of the PICO framework to improve searching PubMed for clinical questions. BMC Med Inform Decis Mak 15(7):16","journal-title":"BMC Med Inform Decis Mak"},{"issue":"10416","key":"4425_CR31","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","volume":"402","author":"G Schett","year":"2023","unstructured":"Schett G, Mackensen A, Mougiakakos D (2023) CAR T-cell therapy in autoimmune diseases. Lancet 402(10416):2034\u20132044","journal-title":"Lancet"},{"issue":"3","key":"4425_CR32","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41409-020-01134-4","volume":"56","author":"VS Sheth","year":"2021","unstructured":"Sheth VS, Gauthier J (2021) Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL. Bone Marrow Transplant 56(3):552\u2013566","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"4425_CR33","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/s41584-024-01210-9","volume":"21","author":"M Stockfelt","year":"2025","unstructured":"Stockfelt M, Teng YKO, Vital EM (2025) Opportunities and limitations of B cell depletion approaches in SLE. Nat Rev Rheumatol 21(2):111\u2013126. https:\/\/doi.org\/10.1038\/s41584-024-01210-9","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"4425_CR34","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1002\/acr.20648","volume":"64","author":"MB Urowitz","year":"2012","unstructured":"Urowitz MB, Gladman DD, Iba\u00f1ez D, Fortin PR, Bae SC, Gordon C et al (2012) Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort. Arthritis Care Res (Hoboken) 64(1):132\u2013137","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"10","key":"4425_CR35","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1136\/ard-2024-225785","volume":"83","author":"W Wang","year":"2024","unstructured":"Wang W, He S, Zhang W, Zhang H, DeStefano VM, Wada M et al (2024) BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial. Ann Rheum Dis 83(10):1304\u20131314","journal-title":"Ann Rheum Dis"},{"issue":"13","key":"4425_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.927153","volume":"10","author":"X Zhang","year":"2022","unstructured":"Zhang X, Zhu L, Zhang H, Chen S, Xiao Y (2022) CAR-T cell therapy in hematological malignancies: current opportunities and challenges. Front Immunol 10(13):927153","journal-title":"Front Immunol"},{"issue":"15","key":"4425_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1476859","volume":"19","author":"J Zhou","year":"2024","unstructured":"Zhou J, Lei B, Shi F, Luo X, Wu K, Xu Y et al (2024) CAR T-cell therapy for systemic lupus erythematosus: current status and future perspectives. Front Immunol 19(15):1476859","journal-title":"Front Immunol"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04425-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04425-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04425-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T07:47:21Z","timestamp":1770882441000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04425-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,14]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["4425"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04425-z","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,14]]},"assertion":[{"value":"1 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The original contributions presented in the study are included in the article\/Supplementary Material; further inquiries can be directed to the corresponding author. Participants\/patients gave written informed consent for their personal or clinical details along with any identifying images to be published in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}